Biotech and healthtech sectors in Southeast Asia are gaining serious traction, backed by national strategies and a growing focus on innovation. Governments across the region are investing in science and technology to future-proof their healthcare systems, such as Singapore’s National Precision Medicine Strategy and Thailand’s “Thailand 4.0” vision, among others. Amidst these emerging trends in biotech and healthtech, there is one key technology that is proving to be a true game-changer: artificial intelligence or AI.
AI is no longer just a support tool in biotech. It is rapidly becoming the engine of innovation. Its applications range from accelerating drug discovery to delivering personalised, data-driven treatments that can fundamentally improve patient outcomes.
Why every app in Southeast Asia wants to be a bank, and how embedded finance is making it happen
As Southeast Asia pushes to become a global innovation hub, the convergence of biotech and AI is opening new doors for startups, researchers, and public health systems.
AI and biotech: A transformative partnership
Artificial intelligence offers exactly what biotech needs: speed, scale, and precision. In areas like genomics and diagnostics, AI systems can analyse vast amounts of biological data faster than human researchers ever could, revealing insights that would take years using traditional methods.
For example, in precision medicine, generative AI is enabling researchers to simulate rare disease scenarios by generating synthetic datasets. This capability is especially important in Southeast Asia, where diverse genetic populations and limited data in certain subgroups make it challenging to develop one-size-fits-all treatments.
Startups and research institutions are now turning to GPU-optimised cloud platforms to crunch genomic data and train complex AI models. These platforms are accelerating progress in fields like immunotherapy and precision oncology, both critical to delivering next-generation healthcare in the region.
Government support and regional readiness
The region’s readiness to adopt AI in biotech is being strengthened by state-led investment and digital infrastructure upgrades. Singapore’s National AI Strategy and Thailand’s push to digitise public healthcare under “Thailand 4.0” are just two examples of how policy is aligning with innovation.
What sets Southeast Asia apart is its demographic diversity and the relative speed at which digital transformation is being embraced. Countries like Indonesia, Vietnam, and Malaysia are already seeing local biotech firms collaborating with AI developers to bring diagnostic tools and treatment planning platforms to underserved communities.
Moreover, institutions across the region are leading the charge in research partnerships, combining deep clinical knowledge with cutting-edge AI capabilities. Earlier this year, Singapore’s A*STAR joined hands with MojiaBio, a leading innovator in green chemistry and sustainable biomanufacturing, to develop an SGD 44.8 million state-of-the-art Sustainable Biomanufacturing Technology Platform (SBTP). Furthermore, Mahidol University in Thailand is undergoing a strategic transformation under the theme “Real World Impact”, aiming to become a world-class leader in health sciences by advancing cell and gene therapy, integrating AI into healthcare, and supporting Thai health tech startups to nurture unicorn-level innovations.
Startup ecosystems adapting to the AI-biotech shift
While the AI boom has presented challenges for some startups in Southeast Asia, those operating at the intersection of AI and biotech are seeing significant opportunities. According to a recent Technode Global report, the region’s biotech scene is ripe for disruption, with AI-driven innovations unlocking new investment channels.
From AI-assisted drug discovery to personalised cancer therapies, the emerging wave of biotech startups is building scalable models with global potential. These companies are increasingly seeking partnerships with pharmaceutical firms, cloud providers, and local governments to move from the pilot stage to real-world implementation.
Despite infrastructure hurdles in some markets, the push towards cloud-native systems, edge computing, and federated learning is helping startups access and analyse data securely. This is a crucial step for any AI-biotech deployment.
What’s next for Southeast Asia’s biotech future?
The integration of AI into biotech is not just a trend, it is a strategic imperative. As health systems across Southeast Asia face rising demand, ageing populations, and emerging health threats, personalised medicine powered by AI offers a sustainable path forward.
Looking ahead, we can expect to see greater collaboration between public health agencies, tech startups, and academic researchers. Investment in AI talent, ethical frameworks for data usage, and cross-border R&D initiatives will be critical to scaling biotech innovation regionally.
If 2025 is to be a pivotal year for progress in biotech, as some global reports predict, Southeast Asia is well-positioned to ride that wave with AI firmly at the helm.